CLPT

Company Overview — What Does ClearPoint Neuro, Inc. Do?

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. ClearPoint Neuro, Inc. (CLPT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Joseph M. Burnett and employs approximately 110 people. With a market capitalization of $271M, CLPT is one of the notable companies in the Healthcare sector.

ClearPoint Neuro, Inc. (CLPT) Stock Rating — Avoid (April 2026)

As of April 2026, ClearPoint Neuro, Inc. receives a Avoid rating with a composite score of 26.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CLPT ranks #4,297 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ClearPoint Neuro, Inc. ranks #783 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLPT Stock Price and 52-Week Range

ClearPoint Neuro, Inc. (CLPT) currently trades at $8.70. The stock lost $0.26 (2.9%) in the most recent trading session. The 52-week high for CLPT is $30.10, which means the stock is currently trading -71.1% from its annual peak. The 52-week low is $8.63, putting the stock 0.8% above its annual trough. Recent trading volume was 686K shares, suggesting relatively thin trading activity.

Is CLPT Overvalued or Undervalued? — Valuation Analysis

ClearPoint Neuro, Inc. (CLPT) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 16.95x, versus the sector average of 2.75x. The price-to-sales ratio is 7.76x, compared to 1.66x for the average Healthcare stock.

At current multiples, ClearPoint Neuro, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ClearPoint Neuro, Inc. Profitability — ROE, Margins, and Quality Score

ClearPoint Neuro, Inc. (CLPT) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -143.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -37.7% versus the sector average of -33.1%.

On a margin basis, ClearPoint Neuro, Inc. reports gross margins of 60.9%, compared to 71.5% for the sector. The operating margin is -64.4% (sector: -66.1%). Net profit margin stands at -65.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 12.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CLPT Debt, Balance Sheet, and Financial Health

ClearPoint Neuro, Inc. has a debt-to-equity ratio of 184.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 6.37x, indicating strong short-term liquidity. Total debt on the balance sheet is $29M. Cash and equivalents stand at $38M.

CLPT has a beta of 1.89, meaning it is more volatile than the broader market — a $10,000 investment in CLPT would be expected to move 88.9% more than the S&P 500 on any given day. The stability factor score for ClearPoint Neuro, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ClearPoint Neuro, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ClearPoint Neuro, Inc. reported revenue of $35M and earnings per share (EPS) of $-0.21. Net income for the quarter was $-23M. Gross margin was 60.9%. Operating income came in at $-22M.

In Q3 2025, ClearPoint Neuro, Inc. reported revenue of $9M and earnings per share (EPS) of $-0.21. Net income for the quarter was $-6M. Gross margin was 63.2%. Revenue grew 9.1% year-over-year compared to Q3 2024. Operating income came in at $-5M.

In Q2 2025, ClearPoint Neuro, Inc. reported revenue of $9M and earnings per share (EPS) of $-0.21. Net income for the quarter was $-6M. Gross margin was 60.3%. Revenue grew 17.3% year-over-year compared to Q2 2024. Operating income came in at $-6M.

In Q1 2025, ClearPoint Neuro, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.22. Net income for the quarter was $-6M. Gross margin was 60.5%. Revenue grew 11.1% year-over-year compared to Q1 2024. Operating income came in at $-6M.

Over the past 8 quarters, ClearPoint Neuro, Inc. has demonstrated a growth trajectory, with revenue expanding from $8M to $35M. Investors analyzing CLPT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLPT Dividend Yield and Income Analysis

ClearPoint Neuro, Inc. (CLPT) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CLPT Momentum and Technical Analysis Profile

ClearPoint Neuro, Inc. (CLPT) has a momentum factor score of 28/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 42/100 reflects moderate short selling activity.

CLPT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ClearPoint Neuro, Inc. (CLPT) ranks #783 out of 838 stocks based on the Blank Capital composite score. This places CLPT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CLPT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLPT vs S&P 500 (SPY) comparison to assess how ClearPoint Neuro, Inc. stacks up against the broader market across all factor dimensions.

CLPT Next Earnings Date

No upcoming earnings date has been announced for ClearPoint Neuro, Inc. (CLPT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLPT? — Investment Thesis Summary

The quantitative profile for ClearPoint Neuro, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Momentum is weak at 28/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, ClearPoint Neuro, Inc. (CLPT) earns a Avoid rating with a composite score of 26.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLPT stock.

Related Resources for CLPT Investors

Explore more research and tools: CLPT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLPT head-to-head with peers: CLPT vs AZN, CLPT vs SLGL, CLPT vs VMD.